Head to head
Bruker Corp vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: BRKR · ABT
BRKR
Bruker Corp
56.46-9.08%
1-year price shape — +29% over the period
Quant Rating C · 76/100
vs
ABT
Abbott Laboratories
103.00-0.84%
1-year price shape — -15% over the period
Quant Rating D · 22/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| BRKR | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 56.46 | 103.00 |
| Change today | -9.08% | -0.84% |
| 1-year return | +29.3% | -15.4% |
| Market cap | $8.62B | $178.39B |
| 52-week range | 32.26 – 68.98 | 80.89 – 126.70 |
| Valuation | ||
| P/E (TTM) | -51.33 | 38.29 |
| P/E percentile, own 5-yr range | 20th | 99th |
| P/B | 3.77 | 3.50 |
| Dividend yield | 0.35% | 2.41% |
| Profitability & growth | ||
| EPS (TTM) | -0.15 | 3.72 |
| Net profit (TTM) | $-22.91M | $6.44B |
| Revenue (TTM) | $3.51B | $48.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +1.6% | +14.5% |
| Gross margin | 47.7% | 56.9% |
| Operating margin | 9.5% | 13.8% |
| Net margin | -4.8% | 9.7% |
| Free cash flow (TTM) | $215.30M | $6.76B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 95.3% | 81.2% |
| Insider activity (12mo) | 26 buy / 23 sell | 36 buy / 12 sell |
| Short interest (% of float) | 7.4% | 1.1% |
| Analyst consensus | 43% buy / 43% hold / 14% sell (7) | 93% buy / 7% hold (15) |
| Analyst price target | $67 (+18%) | $122 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | C (76) | D (22) |
| Company | ||
| Employees | 11,085 | 115,000 |
| Founded | 1960 | 1900 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.